BR112022004432A2 - Cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais - Google Patents

Cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais

Info

Publication number
BR112022004432A2
BR112022004432A2 BR112022004432A BR112022004432A BR112022004432A2 BR 112022004432 A2 BR112022004432 A2 BR 112022004432A2 BR 112022004432 A BR112022004432 A BR 112022004432A BR 112022004432 A BR112022004432 A BR 112022004432A BR 112022004432 A2 BR112022004432 A2 BR 112022004432A2
Authority
BR
Brazil
Prior art keywords
dsm
compositions
bacterial strain
gastrointestinal disorders
treatment
Prior art date
Application number
BR112022004432A
Other languages
English (en)
Inventor
Andrea Biffi
Walter Fiore
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of BR112022004432A2 publication Critical patent/BR112022004432A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais. a presente invenção refere-se a composições compreendendo uma mistura compreendendo ou, alternativamente, consistindo em: a cepa bacteriana bifidobacterium bifidum mimbb23sg ou bbfibs01 (dsm 32708), pelo menos uma ou mais cepas bacterianas selecionadas do grupo a compreendendo as cepas b. breve bbibs01 (dsm 33231), b. breve bbibs02 (dsm 33232), b. animalis subsp. lactis blibs01 (dsm 33233) e l. plantarum lpibs01 (dsm 33234), e opcionalmente, pelo menos mais uma cepa bacteriana selecionada a partir de uma cepa bacteriana l. casei dg® (cncm i-1572) e uma cepa bacteriana l. paracasei lpc-s01? (dsm 26760). por fim, a presente invenção refere-se às ditas composições para uso em um método para o tratamento de doenças, distúrbios ou sintomas gastrointestinais, em particular distúrbios gastrointestinais funcionais, como, por exemplo, síndrome do intestino irritável (ibs).
BR112022004432A 2019-09-20 2020-09-21 Cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais BR112022004432A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000016811A IT201900016811A1 (it) 2019-09-20 2019-09-20 Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
PCT/IB2020/058769 WO2021053636A1 (en) 2019-09-20 2020-09-21 Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
BR112022004432A2 true BR112022004432A2 (pt) 2022-05-31

Family

ID=69375783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004432A BR112022004432A2 (pt) 2019-09-20 2020-09-21 Cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais

Country Status (12)

Country Link
US (1) US20220339216A1 (pt)
EP (1) EP4031157B1 (pt)
JP (1) JP2023507049A (pt)
CN (1) CN114728027A (pt)
AU (1) AU2020347961A1 (pt)
BR (1) BR112022004432A2 (pt)
CA (1) CA3154976A1 (pt)
IL (1) IL291445A (pt)
IT (1) IT201900016811A1 (pt)
MX (1) MX2022003372A (pt)
PT (1) PT4031157T (pt)
WO (1) WO2021053636A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
IT202100018740A1 (it) * 2021-07-15 2023-01-15 Sofar Spa Uso di ceppi di batteri Lactobacillus paracasei nel trattamento di neonati
CN117085042A (zh) * 2023-10-20 2023-11-21 潍坊君薇生物科技有限责任公司 两歧双歧杆菌bl002后生元及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754300C (en) * 2009-03-05 2020-02-25 Probiotical S.P.A. Bacteria strains having a high anti-inflammatory activity
EP2496241B1 (en) * 2009-11-02 2013-08-28 Compagnie Gervais Danone Method for reducing gastro-intestinal inflammation using bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria
EP2481299B1 (en) * 2011-01-31 2016-12-07 Dr. Fischer Gesundheitsprodukte GmbH Bifidobacterium bifidum strains for application in gastrointestinal diseases

Also Published As

Publication number Publication date
MX2022003372A (es) 2022-04-11
IL291445A (en) 2022-05-01
CN114728027A (zh) 2022-07-08
PT4031157T (pt) 2024-04-30
EP4031157A1 (en) 2022-07-27
EP4031157B1 (en) 2024-02-28
AU2020347961A1 (en) 2022-03-31
US20220339216A1 (en) 2022-10-27
CA3154976A1 (en) 2021-03-25
WO2021053636A1 (en) 2021-03-25
JP2023507049A (ja) 2023-02-21
IT201900016811A1 (it) 2021-03-20

Similar Documents

Publication Publication Date Title
BR112022004432A2 (pt) Cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais
BR112022004569A2 (pt) Cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais
Alavi et al. Interpersonal gut microbiome variation drives susceptibility and resistance to cholera infection
EP3639834B1 (en) Use of microbial communities for human and animal health
BR112022004527A2 (pt) Composições com base em cepas bacterianas e seu uso como anti-inflamatórios
Chen et al. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells
Plé et al. Combining selected immunomodulatory Propionibacterium freudenreichii and Lactobacillus delbrueckii strains: reverse engineering development of an anti‐inflammatory cheese
Abdelhamid et al. Probiotic Lactobacillus and Bifidobacterium strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining
Vemuri et al. Role of lactic acid probiotic bacteria in IBD
BR112022004976A2 (pt) Composições com base em cepas bacterianas e extratos de baga e uso do mesmo como anti-inflamatórios
EP4272815A3 (en) New medical use of probiotics
Seddik et al. Anti-pathogenic and probiotic attributes of Lactobacillus salivarius and Lactobacillus plantarum strains isolated from feces of Algerian infants and adults
US20130195823A1 (en) Use of lactobscilli inhibiting gas products coliform bacteria isolated from infants affected by colic
US20120128633A1 (en) Use of collinsella aerofaciens for reducing bloating
RU2007106038A (ru) Композиция на основе пробиотических бактерий и ее применение в профилактике и/или лечении респираторных патологий и/или инфекций и в улучшении функции кишечника
Garriga et al. Potentially probiotic and bioprotective lactic acid bacteria starter cultures antagonise the Listeria monocytogenes adhesion to HT29 colonocyte-like cells
BR112019001116A2 (pt) composição probiótica usada no tratamento e/ou prevenção da dermatite atópica
IT201600127498A1 (it) Probiotici per uso nella diverticolosi e malattia diverticolare
Zanini et al. The effects of fermented milks with simple and complex probiotic mixtures on the intestinal microbiota and immune response of healthy adults and children
Park et al. Effect of Lactobacillus plantarum FH185 on the reduction of adipocyte size and gut microbial changes in mice with diet-induced obesity
Tanriover et al. Use of probiotics in various diseases: Evidence and promises
Mokrani et al. Grape seed and skin extract, a potential prebiotic with anti-obesity effect through gut microbiota modulation
Rocchetti et al. Immunomodulatory activity on human macrophages by cell-free supernatants to explore the probiotic and postbiotic potential of Lactiplantibacillus plantarum strains of plant origin
EP2519255A2 (en) Probiotic bifidobacterial composition in accordance with secretor blood group status
Baig et al. An Overview of Dairy Microflora